目的:本研究旨在探讨转移体积测量之间的关系,骨骼相关事件,以及诊断为乳腺癌和骨转移的女性的生存率。
方法:这项回顾性研究是对82名女性乳腺癌患者进行的(平均年龄:53±14.3岁;范围,23至87岁)诊断,治疗,并在2005年1月至2019年12月期间进行了随访。收集的数据包括转移部位的信息和骨骼相关事件的存在。以两种方式测量转移体积:转移的数量(从高到低)和它们的定位(第一种,第二,和第三组)。第一组由椎骨组成,肋骨,胸骨,和颅骨;第二组包括肩胛骨,锁骨,肱骨近端,和股骨近端区域;第三组包括股骨和肱骨骨干和远端区域,以及其他长骨的转移区域。
结果:63例(76.8%)患者被诊断为导管癌。一半的患者在最初诊断时就有骨转移,62例(75.6%)发生骨骼相关事件,30例(36.6%)患者发生至少3例事件。骨痛是最常见的骨骼相关事件。在基于骨转移的定位和骨骼数量的转移体积测量与骨骼相关事件的发生之间没有发现相关性(每个p>0.05)。从首次诊断开始,患者的生存时间为1至231个月(中位数:56.8个月)。高转移体积的患者,第三组的人,那些骨盆和肺受累的人,老年患者的生存时间较短(P<0.05)。
结论:研究表明,测量转移体积可能是评估乳腺癌骨转移患者生存率的关键因素。未来的前瞻性和随机对照研究可以探索这种测量的潜力,以创建实用的临床工具。
OBJECTIVE: The study aimed to investigate the relationship between metastatic volume measurement, skeletal-related events, and survival in women diagnosed with breast cancer and bone metastases.
METHODS: This retrospective study was conducted with 82 female breast cancer patients (mean age: 53±14.3 years; range, 23 to 87 years) diagnosed, treated, and followed up between January 2005 and December 2019. The collected data included information on metastasis sites and the presence of skeletal-related events. Metastatic volume was measured in two ways: the number of metastases (high to low) and their localization (the first, second, and third groups). The first group consisted of vertebrae, ribs, sternum, and calvarial bones; the second group included scapula, clavicle, proximal humerus, and proximal femur regions; the third group consisted of femur and humerus diaphyseal and distal regions, as well as metastasis regions in other long bones.
RESULTS: Sixty-three (76.8%) patients were diagnosed with ductal carcinoma. Half of the patients had bone metastases at the time of initial diagnosis, while 62 (75.6%) experienced skeletal-related events, with at least three events occurring in 30 (36.6%) patients. Bone pain was the most common skeletal-related event. No correlation was found between metastatic volume measurement based on the localization of bone metastases and the number of bones and the occurrence of skeletal-related events (p>0.05 for each). Patients\' survival time spanned from one to 231 months (median: 56.8 months) from their first diagnosis. Patients with high metastatic volume, those in the third group, those whose pelvis and lung were involved, and elderly patients had a shorter survival time (p<0.05 for each).
CONCLUSIONS: The study indicates that measuring metastatic volume may be a critical factor in evaluating the survival of breast cancer patients with bone metastases. Future prospective and randomized controlled studies can explore the potential of this measurement to create practical clinical tools.